246 related articles for article (PubMed ID: 20172070)
41. Foveal function and thickness after verteporfin photodynamic therapy in central serous chorioretinopathy with hyperautofluorescent subretinal deposits.
Pryds A; Larsen M
Retina; 2013 Jan; 33(1):128-35. PubMed ID: 23269407
[TBL] [Abstract][Full Text] [Related]
42. Long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy.
Tseng CC; Chen SN
Br J Ophthalmol; 2015 Aug; 99(8):1070-7. PubMed ID: 25680621
[TBL] [Abstract][Full Text] [Related]
43. Clinical research on one-third dose verteporfin photodynamic therapy in the treatment of chronic central serous chorioretinopathy.
Hua L; Lin B; Hong J; Min HB; Han WL; Zhou TY; Zhang ZQ
Eur Rev Med Pharmacol Sci; 2018 Jan; 22(2):278-284. PubMed ID: 29424884
[TBL] [Abstract][Full Text] [Related]
44. Half-dose Versus Half-time Photodynamic Therapy for Central Serous Chorioretinopathy.
Liu HY; Yang CH; Yang CM; Ho TC; Lin CP; Hsieh YT
Am J Ophthalmol; 2016 Jul; 167():57-64. PubMed ID: 27084002
[TBL] [Abstract][Full Text] [Related]
45. Photodynamic therapy for chronic central serous chorioretinopathy.
Ruiz-Moreno JM; Lugo FL; Armadá F; Silva R; Montero JA; Arevalo JF; Arias L; Gómez-Ulla F
Acta Ophthalmol; 2010 May; 88(3):371-6. PubMed ID: 19958296
[TBL] [Abstract][Full Text] [Related]
46. [Observation on long-term efficacy of half-dose photodynamic therapy with chronic central serous chorioretinopathy using optical coherence tomography].
Liu Y; Li L; Xu G; Wang W
Zhonghua Yan Ke Za Zhi; 2016 May; 52(5):328-34. PubMed ID: 27220704
[TBL] [Abstract][Full Text] [Related]
47. Change of regional choroid thickness after reduced-fluence photodynamic therapy for chronic central serous chorioretinopathy.
Manabe S; Shiragami C; Hirooka K; Izumibata S; Tsujikawa A; Shiraga F
Am J Ophthalmol; 2015 Apr; 159(4):644-51. PubMed ID: 25595669
[TBL] [Abstract][Full Text] [Related]
48. [Photodynamic therapy for chronic central serous chorioretinopathy and diffuse retinal epitheliopathy].
Cornut PL; Quaranta-El Maftouhi M; Mauget-Faÿsse M
J Fr Ophtalmol; 2012 Feb; 35(2):82-7. PubMed ID: 21889817
[TBL] [Abstract][Full Text] [Related]
49. Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea.
van Dijk EHC; Dijkman G; Boon CJF
Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2029-2035. PubMed ID: 28674835
[TBL] [Abstract][Full Text] [Related]
50. Retinal sensitivity after photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy: short-term results.
Fujita K; Yuzawa M; Mori R
Retina; 2011 Apr; 31(4):772-8. PubMed ID: 20890236
[TBL] [Abstract][Full Text] [Related]
51. Comparison of visual and anatomical outcomes of half-fluence and half-dose photodynamic therapy in eyes with chronic central serous chorioretinopathy.
Kim YK; Ryoo NK; Woo SJ; Park KH
Graefes Arch Clin Exp Ophthalmol; 2015 Dec; 253(12):2063-73. PubMed ID: 25616728
[TBL] [Abstract][Full Text] [Related]
52. Long-term results of low-fluence photodynamic therapy for chronic central serous chorioretinopathy.
Leys E; Tuttle S; Rasquin F; Neu F; Postelmans L
J Fr Ophtalmol; 2015 Oct; 38(8):709-16. PubMed ID: 26345542
[TBL] [Abstract][Full Text] [Related]
53. Effect of Photodynamic Therapy on Optical Coherence Tomography Angiography in Eyes with Chronic Central Serous Chorioretinopathy.
Xu Y; Su Y; Li L; Qi H; Zheng H; Chen C
Ophthalmologica; 2017; 237(3):167-172. PubMed ID: 28171871
[TBL] [Abstract][Full Text] [Related]
54. System review and meta-analysis on photodynamic therapy in central serous chorioretinopathy.
Ma J; Meng N; Xu X; Zhou F; Qu Y
Acta Ophthalmol; 2014 Dec; 92(8):e594-601. PubMed ID: 25042260
[TBL] [Abstract][Full Text] [Related]
55. The efficacy of intravitreal bevacizumab for idiopathic central serous chorioretinopathy.
Lim JW; Kim MU
Graefes Arch Clin Exp Ophthalmol; 2011 Jul; 249(7):969-74. PubMed ID: 21140161
[TBL] [Abstract][Full Text] [Related]
56. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study.
Yannuzzi LA; Slakter JS; Gross NE; Spaide RF; Costa D; Huang SJ; Klancnik JM; Aizman A
Retina; 2003 Jun; 23(3):288-98. PubMed ID: 12824827
[TBL] [Abstract][Full Text] [Related]
57. Half-time photodynamic therapy for central serous chorioretinopathy.
Tsai MJ; Hsieh YT
Optom Vis Sci; 2014 Sep; 91(9):1140-5. PubMed ID: 25083838
[TBL] [Abstract][Full Text] [Related]
58. OCT Angiography Compared to Fluorescein and Indocyanine Green Angiography in Chronic Central Serous Chorioretinopathy.
Teussink MM; Breukink MB; van Grinsven MJ; Hoyng CB; Klevering BJ; Boon CJ; de Jong EK; Theelen T
Invest Ophthalmol Vis Sci; 2015 Aug; 56(9):5229-37. PubMed ID: 26244299
[TBL] [Abstract][Full Text] [Related]
59. Long-term results of half-fluence photodynamic therapy for chronic central serous chorioretinopathy.
Rouvas A; Stavrakas P; Theodossiadis PG; Stamatiou P; Milia M; Giannakaki E; Datseris I
Eur J Ophthalmol; 2012; 22(3):417-22. PubMed ID: 21928269
[TBL] [Abstract][Full Text] [Related]
60. Early choriocapillaris changes after half-fluence photodynamic therapy in chronic central serous chorioretinopathy evaluated by optical coherence tomography angiography: Preliminary results.
Demircan A; Yesilkaya C; Alkin Z
Photodiagnosis Photodyn Ther; 2018 Mar; 21():375-378. PubMed ID: 29409857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
